Əsas səhifə

Çap

Əks əlaqə

İnfo
Prevention of bone disease in kidney transplant recipients

Mündəricat

Prevention of bone disease in kidney transplant recipients

Sübutlu məlumatların xülasələri
26.07.2017 • Sonuncu dəyişiklik 26.07.2017
Editors

Treatment with a bisphosphonate, vitamin D sterol or calcitonin after kidney transplantation may protect against immunosuppression-induced reductions in bone mineral density and prevent fracture.

A Cochrane review included 24 studies with a total of 1 299 subjects. No individual intervention (bisphosphonates, vitamin D sterol or calcitonin) was associated with a reduction in fracture risk compared with placebo. Combining results for all active interventions against placebo demonstrated any treatment of bone disease was associated with a reduction in the RR of fracture (RR 0.51, 95% CI 0.27 to 0.99). Bisphosphonates (any route), vitamin D sterol, and calcitonin all had a beneficial effect on the bone mineral density at the lumbar spine. Bisphosphonates and vitamin D sterol also had a beneficial effect on the bone mineral density at the femoral neck. Bisphosphonates had greater efficacy for preventing bone mineral density loss when compared head-to-head with vitamin D sterols.

Comment: The quality of evidence is downgraded by limitations in study quality (e.g. unclear allocation concealment, inadequate intention-to-treat adherence, small sample sizes) and by inconsistency (heterogeneity in study populations, interventions and outcomes).

Ədəbiyyat

  1. Palmer SC, McGregor DO, Strippoli GF. Interventions for preventing bone disease in kidney transplant recipients. Cochrane Database Syst Rev 2007 Jul 18;(3):CD005015.